Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis
- 1.4k Downloads
Adequate surgical resection remains the treatment of choice for tenosyovial giant cell tumor (TGCT). However, diffuse type TGCT (D-TGCT) is more difficult to resect and has a higher rate of recurrence (up to 50 %), which is often multiple. D-TGCT is rarely lethal and only rare cases of metastases have been described. Nevertheless, patients might have a significant decline in their quality of life due to multiple operations, which may sometimes result in a partial loss of function of the affected joint and may also be associated with perioperative morbidity and secondary arthrosis. As of today, no systemic treatment is approved for this rare disease. The aims of systemic therapy in the context of a non-lethal tumor are to reduce surgical morbidity and to preserve function and patient quality of life. Because TGCT is associated with characteristic cytogenetic abnormalities resulting in the overexpression of CSF1, systemic therapies targeting the CSF1/CSF1R axis (imatinib, nilotinib, emactuzumab, and PLX3397) have been tested in patients with locally advanced or relapsed D-TGCT. The more recent and more specific CSF1R inhibitors have shown a very interesting clinical activity with acceptable toxicity in early phase trials. These results will need to be confirmed in larger, ideally randomized, trials. But the high rate of clinical and functional improvement seen in some patients with advanced D-TGCT, often after multiple operations, suggests that these inhibitors will likely have a role in the management of patients with an inoperable disease; the definition of “inoperable TGCT” still requires refinement to reach a consensus. Another point that will need to be addressed is that of “the optimal duration of therapy” for these patients. Indeed, we and others have observed often prolonged clinical benefit and symptomatic relief even after treatment was stopped, with both monoclonal antibodies and tyrosine kinase inhibitors. Responses were observed very early on with emactuzumab and PLX3397, and patients experienced significant symptom improvement within a few weeks of starting therapy (2–4 weeks). Another possible application of CSF1R inhibitors could be used either as a preoperative or postoperative therapy for patients with operable TGCT. However, we currently lack sufficient follow-up to adequately address these questions which will each require specific trial designs. Overall, the striking clinical activity of CSF1R specific inhibitors in TGCT has created great enthusiasm among clinicians, and further development of these agents is clearly medically needed. Nevertheless, further investigations are necessary to validate those treatments and assess how to best incorporate them among other treatment modalities into the overall therapeutic strategy for a given patient.
KeywordsTenosynovial giant cell tumor Pigmented villonodular synovitis Systemic therapy Imatinib Colony-stimulating factor 1 Colony-stimulating factor 1 receptor Anti-TNF-alpha Imatinib Nilotinib Emactuzumab PLX3397
Mehdi Brahmi and Armelle Vinceneux contributed equally to this work.
Compliance with Ethical Standards
Conflict of Interest
Mehdi Brahmi declares that he has no conflict of interest.
Armelle Vinceneux declares that she has no conflict of interest.
Philippe A. Cassier has received research funding through grants from Roche and Novartis, as well as non-financial research support from Plexxikon, and has also received compensation from Roche and Novartis for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 6.WHO. Classification of tumours of soft tissue and bone. 4th ed. Lyon: World Health Organization; 2013.Google Scholar
- 7.Yoon H-J, Cho Y-A, Lee J-I, Hong S-P, Hong S-D. Malignant pigmented villonodular synovitis of the temporomandibular joint with lung metastasis: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:e30–6. doi: 10.1016/j.tripleo.2010.11.031.CrossRefPubMedGoogle Scholar
- 13.West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103:690–5. doi: 10.1073/pnas.0507321103. CSF1 overexpression by these cells.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O'Connell JX, Huntsman D, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007;31:970–6. doi: 10.1097/PAS.0b013e31802b86f8.CrossRefPubMedGoogle Scholar
- 15.Macrophages—advances in research and application: 2012 Edition. ScholarlyEditions. 2012.Google Scholar
- 31.••Blay J-Y, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008;19:821–2. doi: 10.1093/annonc/mdn033. This single patient report is the first proof of concept for therapeutically targeting the CSF1/CSF1R axis in patients with advanced TGCT/PVNS.CrossRefGoogle Scholar
- 32.Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012;118:1649–55. doi: 10.1002/cncr.26409.CrossRefPubMedGoogle Scholar
- 35.Gelderblom H, Pérol D, Chevreau C, Tattersall MNH, Stacchiotti S, Casali PG, et al. An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. J Clin Oncol. Available: http://meetinglibrary.asco.org/content/98976-114.
- 37.••Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16:949–56. doi: 10.1016/S1470-2045(15)00132-1. Report on the efficacy of newer, more specific CSF1R inhibitors in TGCT, confirming the major role of this pathway in this rare disease.CrossRefPubMedGoogle Scholar
- 38.••Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373:428–37. doi: 10.1056/NEJMoa1411366. Report on the efficacy of newer, more specific CSF1R inhibitors in TGCT, confirming the major role of this pathway in this rare disease.CrossRefPubMedGoogle Scholar
- 39.Sikaria S, Heim-Hall J, Diaz EH, Williams R, Sankhala K, Laabs B, et al. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. Target Oncol. 2014;9:73–9. doi: 10.1007/s11523-013-0267-8.CrossRefPubMedGoogle Scholar
- 40.Cassier PA, Maki RG, Wagner AJ, Bompas E, Gelderblom H, Kroep JR, et al. Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT). ASCO Meet Abstr. 2015;33:10561.Google Scholar